Mining protein dynamics from sets of crystal structures using "consensus structures"

Protein Science

Volumn 19, Issue 4, 2010, Pages 742-752

  Van Westen, Gerard J P ^a   Wegner, Jörg K ^b   Bender, Andreas ^a   IJzerman, Adriaan P ^a   Van Vlijmen, Herman W T ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b Virco BVBA   (Belgium)

Author keywords

B factors; Flexibility; Ligand induced conformational changes; Pocket characterization; Working mechanism

Indexed keywords

DELAVIRDINE; EFAVIRENZ; LIGAND; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CONSENSUS SEQUENCE; CONSENSUS STRUCTURE; CRYSTAL STRUCTURE; ENZYME BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; TECHNIQUE; WILD TYPE;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DATA MINING; DATABASES, PROTEIN; HIV REVERSE TRANSCRIPTASE; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77950271945     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.350     Document Type: Article

References (40)

1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank.Nucleic Acids Res 28:235-242.
2. Knegtel RM, Kuntz ID, Oshiro CM (1997) Molecular docking to ensembles of protein structures.J Mol Biol 266:424-440.
3. Yuan Z, Bailey TL, Teasdale RD (2005) Prediction of protein B-factor profiles.Proteins 58:905-912.
4. Wampler JE (1997) Distribution analysis of the variation of B-factors of X-ray crystal structures; temperature and structural variations in lysozyme.J Chem Inf Comput Sci 37:1171-1180.
5. Yuan Z, Zhao J, Wang Z-X (2003) Flexibility analysis of enzyme active sites by crystallographic temperature factors.Protein Eng 16:109-114.
6. Keller PA, Leach SP, Luu TTT, Titmuss SJ, Griffith R (2000) Development of computational and graphical tools for analysis of movement and flexibility in large molecules.J Mol Graph Model 18:235-241, 299.
7. Richmond N, Abrams C, Wolohan P, Abrahamian E, Willett P, Clark R (2006) GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D.J Comput-Aided Mol Des 20:567-587.
8. Totrov M (2008) Atomic property fields: generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR.Chem Biol Drug Des 71:15-27.
9. O'Brien SE, Brown DG, Mills JE, Phillips C, Morris G (2005) Computational tools for the analysis and visualization of multiple protein-ligand complexes.J Mol Graph Model 24:186-194.
10. Powers RA, Shoichet BK (2002) Structure-based approach for binding site identification on AmpC beta-lactamase. J Med Chem 45:3222-3234.
11. Nichols SE, Domaoal RA, Thakur VV, Tirado-Rives J, Anderson KS, Jorgensen WL (2009) Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures.J Chem Inf Model 49:1272-1279.
12. Mitsuya H, Weinhold KJ, Furman PA,St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S (1985) 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proc Natl Acad Sci USA 82:7096-7100.
13. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.J Virol 68:1660-1666.
14. Havlir DV, Eastman S, Gamst A, Richman DD (1996) Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.J Virol 70:7894-7899.
15. Rhee S-Y, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, Horberg M, Flamm J, Follansbee S, Schapiro JM, Shafer RW (2005) HIV-1 protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.J Infect Dis 192:456-465.
16. Johnson V, Brun-Vezinet F, Clotet B, Gunthard H, Kuritzkes D, Pillay D, Schapiro J, Richman D (2008) Update of the drug resistance mutations in HIV-1: December 2008.Top HIV Med 16:138-145.
17. Zhou Z, Madrid M, Evanseck JD, Madura JD (2005) Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase. J Am Chem Soc 127:17253-17260.
18. Madrid M, Lukin JA, Madura JD, Ding J, Arnold E (2001) Molecular dynamics of HIV-1 reverse transcriptase indicates increased flexibility upon DNA binding.- Proteins 45:176-182.
19. Bahar I, Erman B, Jernigan RL, Atilgan AR, Covell DG (1999) Collective motions in HIV-1 reverse transcriptase: examination of flexibility and enzyme function. J Mol Biol 285:1023-1037.
20. Das K, Sarafianos SG, Clark AD, Jr, Boyer PL, Hughes SH, Arnold E (2007) Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside Inhibitor HBY 097.J Mol Biol 365:77-89.
21. Carlson HA (2002) Protein flexibility and drug design: how to hit a moving target.Curr Opin Chem Biol 6:447-452.
22. Carlson HA, McCammon JA (2000) Accommodating protein flexibility in computational drug design.Mol Pharmacol 57:213-218.
23. Hsiou Y, Ding J, Das K, Clark AD, Jr, Hughes SH, Arnold E (1996) Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms.Structure 4:853-860.
24. Das K, Bauman JD, Clark AD, Jr, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E (2008) High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.Proc Natl Acad Sci USA 105:1466-1471.
25. Rodriguez-Barrios F, Balzarini J, Gago F (2005) The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.J Am Chem Soc 127:7570-7578.
26. Maga G, Radi M, Zanoli S, Manetti F, Canciano R, Hubscher U, Spadari S, Falciani C, Terrazas M, Vilarrasa J, Botta M (2007) Discovery of non-nucleoside inhibitors of HIV-1 reverse transcriptase competing with the nucleoside substrate.Angew Chem Int Ed Engl 46:1810-1813.
27. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.Nat Struct Biol 2:303-308.
28. Balzarini J (2004) Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.Curr Top Med Chem 4:921-944.
29. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
30. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, Arnold E (2009) Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.J Mol Biol 385:693-713.
31. Mendieta J, Cases-Gonzalez CE, Matamoros T, Ramirez G, Menendez-Arias L (2008) A Mg2+-induced conformational switch rendering a competent DNA polymerase catalytic complex.Proteins 71:565-574.
32. Paris KA, Haq O, Felts AK, Das K, Arnold E, Levy RM (2009) Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures. J Med Chem 52:6413-6420.
33. Wegner JK, Vlijmen HV, Boutton CWM (2008) Phenotype prediction method. PatentWO2008065180A1; EP2007063047.
34. Sweeney ZK, Harris SF, Arora N, Javanbakht H, Li Y, Fretland J, Davidson JP, Billedeau JR, Gleason SK, Hirschfeld D, Kennedy-Smith JJ, Mirzadegan T, Roetz R, Smith M, Sperry S, Suh JM, Wu J, Tsing S, Villaseñor AG, Paul A, Su G, Heilek G, Hang JQ, Zhou AS, Jernelius JA, Zhang F-J, Klumpp K (2008) Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.J Med Chem 51:7449-7458.
35. Wang Z, Wu B, Kuhen KL, Bursulaya B, Nguyen TN, Nguyen DG, He Y (2006) Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.Bioorg Med Chem Lett 16:4174-4177.
36. Parkin NT, Gupta S, Chappey C, Petropoulos CJ (2006) The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.Antimicrob Agents Chemother 50:351-354.
37. Gerondelis P, Archer RH, Palaniappan C, Reichman RC, Fay PJ, Bambara RA, Demeter LM (1999) The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 50-end- and DNA 3′-end-directed RNase H activities.J Virol 73:5803-5813.
38. ICM, Version 3.6d. La Jolla: Molsoft L.L.C.; 2009.
39. Marvin Beans pKa Prediction tool, Version 4.1. Budapest: ChemAxon, 2006.
40. Najmanovich R (2000) Side-chain flexibility in proteins upon ligand binding.Proteins 39:261-268.